Benzyl 3,5-dioxopiperidine-1-carboxylate → HCID 136242929, Verbindung
Reaktionsgleichung
Br[C:2]1[C:11]([NH2:12])=[CH:10][C:9]([F:13])=[CH:8][C:3]=1[C:4]([O:6]C)=O.O=C1CC(=O)CN(C(OCC2C=CC=CC=2)=O)C1.[CH3:32][N:33]([CH3:53])[CH2:34][CH2:35][N:36]1[CH2:48][C:47]2NC3C=CC=C4C(=O)[NH:50][N:51]=[C:38]([C:39]=2C=34)[CH2:37]1>>[CH3:32][N:33]([CH3:53])[CH2:34][CH2:35][N:36]1[CH2:48][C:47]2[NH:12][C:11]3[CH:10]=[C:9]([F:13])[CH:8]=[C:3]4[C:4](=[O:6])[NH:50][N:51]=[C:38]([C:39]=2[C:2]=34)[CH2:37]1Komponenten
4
Versuchsvorschrift
Compound 61 was prepared from methyl 2-bromo-5-fluoro-3-aminobenzoate and benzyl 3,5-dioxopiperidine-1-carboxylate according to the procedures similar to those for Compound 60. 1H NMR δ 10.1 (s, 1H), 7.58 (dd, 1H, J=1.8, 10.2 Hz), 7.21 (dd, 1H, J=1.8, 10.2 Hz), 4.20-4.22 (m, 2H), 4.03 (s, 2H), 3.42 (s, 2H), 2.51-2.54 (m, 2H), and 2.19 (s, 6H). MS (ESI) m/e [M+1]+316.